Nadeem Anwar, MD
Transplant Hepatology · Cincinnati, OHNPI 1487644746
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $3,610 of the $5,110 with a category attached, or 70.6%. Gilead accounts for 74.8% of it on its own, with 15 other manufacturers making up the rest. Reporting peaked in 2020 at $4,016 and has fallen 96.3% since, to $150 in 2025.
Across 23 payments — averaging $222.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Gilead$4K
- Amgen$315
- Intercept Pharmaceuticals, Inc.$248
- Evoke Pharma, Inc.$162
- Ipsen Biopharmaceuticals, Inc$115
- AbbVie$109
- plus $340 from 10 others
Across 18 payments — averaging $894.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bausch Health US, LLC$15K
- Gilead$2K
What the payments were for
- Consulting fees$3,61071%
- Travel & lodging$1363%
- Food & beverage$1,36427%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Gilead | 4 | $3,822 |
| Amgen | 3 | $315 |
| Intercept Pharmaceuticals, Inc. | 2 | $248 |
| Evoke Pharma, Inc. | 1 | $162 |
| Ipsen Biopharmaceuticals, Inc | 1 | $115 |
| AbbVie | 1 | $109 |
| Sanofi | 1 | $80 |
| Akcea Therapeutics, Inc. | 1 | $72 |
| Madrigal Pharmaceuticals | 2 | $38 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $37 |
| Pfizer | 1 | $27 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $24 |
| Celltrion USA Inc. | 1 | $18 |
| Cook Medical LLC | 1 | $18 |
| Boston Scientific | 1 | $14 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few transplant hepatology providers in Ohioto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Lactulose | 17 | $684 |
| Carvedilol | 11 | $83 |
Paid to pharmacies, not to this prescriber.
Other transplant hepatology in Cincinnati
- Khurram BariCincinnati$124K
- Kenneth ShermanCincinnati$43K
- Alexander LalosCincinnati$15K
- Amoah Yeboah-KorangCincinnati$246
- Anthony MichaelsColumbus$380K
- Pranav PennintiColumbus$563
- Ruchi BhatiaColumbus$374
- Naemat SandhuCleveland$262
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.